Insights into endometrial serous carcinogenesis and progression

Area of Science:

• Gynecologic Oncology
• Molecular Pathology
• Cancer Genomics

Background:

• Endometrial serous carcinoma (ESC) is a rare but aggressive subtype of endometrial cancer.
• ESC has a significantly higher case-fatality rate compared to endometrioid endometrial cancer.
• The molecular drivers and evolutionary pathways of ESC remain largely undefined.

Purpose of the Study:

• To review the current understanding of endometrial serous carcinogenesis.
• To identify key molecular alterations and potential precursor lesions in ESC.
• To explore potential targets for early detection and therapeutic intervention.

Main Methods:

• Review of existing literature on ESC molecular pathology and carcinogenesis.
• Analysis of immunohistochemistry (IHC) and gene expression profiling data for key markers.
• Examination of morphologic precursor lesions and genetic instability markers.

Main Results:

• TP53 gene mutations (22.7-96%) and p53 protein overexpression (~76%) are frequent in ESC.
• Upregulation of p16 and dysregulation of cell cycle pathways (p16INKA/CDK/pRb and ARF-MDM2-p53) are observed.
• HER2/neu overexpression (~32.1%) and genetic instability (e.g., LOH at 1p32-33) are common features.
• Endometrial glandular dysplasia (EmGD) is identified as a likely morphologic precursor.
• "p53 signatures" in morphologically normal cells are associated with ESC and may initiate a progression model.

Conclusions:

• ESC likely arises through multiple pathways with early molecular events.
• Dysregulation of cell cycle control and genetic instability are critical in ESC development.
• Identification of precursor lesions like EmGD and "p53 signatures" offers promise for early ESC detection and improved patient outcomes.